Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Primary and study completion pushed from Oct 2026 to Oct 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT03607890 Registry history of NCT03607890 on ClinicalTrials.gov (opens the registry)